Between The Lines


Routine Clinical Practice Comparison of IRD and Rd in RR Multiple Myeloma

January 19th 2022

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

The Role of Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer

December 23rd 2021

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia

December 22nd 2021

Clinical Practice Experience with Avelumab First-Line Maintenance in Urothelial Carcinoma

December 22nd 2021

Daniel Petrylak, MD and Donald Barry Boyd, MD, MS review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.

18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence

December 22nd 2021

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

Immune Checkpoint Inhibitors as Switch or Continuous Maintenance Therapy in Solid Tumors: Rationale and Current State

December 3rd 2021

Drs. Gupta and Brown discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Incorporating Real-World Evidence into Clinical Decisions in NSCLC

October 21st 2021

Lyudmila Bazhenova, MD, and Frederico Albrecht, MD, consider when to refer to a clinical trial data and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on a recent publication by Bassel Nazha, MD, MPH.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

October 15th 2021

Key takeaways from a recent study of tipifarnib as treatment for recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers

October 8th 2021

Experts collaborate to share and reflect on data from an eNRGy1 global registry study, which analyzed therapy in NRG1 fusion–driven lung cancers.

Circulating Tumor DNA as a Biomarker of Progression in Colorectal Cancer

October 8th 2021

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” and consider how to apply the paper’s findings into clinical practice.